ReviewMaterials today. Bio2025
Recent advances in phototherapy-based nanomedicine of lymphoma.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advancements in Nanomedicine for Precision Management of Lymphoma: Mechanisms, Diagnostics, and Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Carrier-free nanoparticles based on natural products trigger dual "synergy and attenuation" for enhanced phototherapy of liver cancer.Materials today. Bio · 2025Article
- Recent trends in mesoporous carbon-based nanoplatforms for biomedical application.Journal of pharmaceutical analysis · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphoma comprises a heterogeneous group of hematologic malignancies with varying prognoses and treatment responses. Conventional therapies including chemotherapy, immunotherapy, and targeted therapy have improved patient outcomes. However, challenges such as relapse, treatment resistance, and systemic toxicity remain significant concerns. Phototherapy, including photodynamic and photothermal therapies, has emerged as a promising alternative owing to its minimally invasive nature, tumor-specific activation, and potential to enhance antitumor immunity. Photo-activated agents and thermal effects of phototherapy induce tumor cell death while stimulating antitumor immune responses. Recent advances in nanomedicine have further improved the efficacy of phototherapy by enabling targeted drug delivery, controlled photosensitizer release, and enhanced tumor penetration. Despite these advances, limitations such as optimizing light penetration, improving selectivity, and integrating phototherapy into existing treatment regimens require further exploration. This review summarizes recent progress in phototherapy for lymphoma, highlights key preclinical findings, discusses current limitations, and outlines future directions for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.